These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2972104)

  • 1. Effect of long-acting LHRH analog (Zoladex) on prostate cancer: evaluated by transrectal ultrasonography.
    Drago JR; Nesbitt JA; Cirulli C
    Urology; 1988 Oct; 32(4):285-7. PubMed ID: 2972104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
    Geldof AA; de Voogt HJ; Rao BR
    Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA; Calle Fernández JR
    Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
    [No Abstract]   [Full Text] [Related]  

  • 5. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic prostate carcinoma with the depot LRH analog Zoladex.
    Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; List A; Rutland M; Knox BS
    Prostate; 1988; 12(2):119-27. PubMed ID: 2966931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
    J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic evaluation of the effect of LHRH analog on prostatic cancer using transrectal ultrasonotomography.
    Kojima M; Watanabe H; Ohe H; Miyashita H; Inaba T
    Prostate; 1987; 10(1):11-7. PubMed ID: 3103113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 10. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 11. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Lunglmayr G
    Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
    [No Abstract]   [Full Text] [Related]  

  • 12. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
    Chodak GW
    Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
    Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
    Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary hyperplasia after goserelin (LHRH-analogue) therapy.
    Radner H; Pummer K; Lax S; Wandschneider G; Höfler H
    Neuropathol Appl Neurobiol; 1991 Feb; 17(1):75-81. PubMed ID: 1647501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
    Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoladex treatment of symptomatic prostatic carcinoma.
    Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
    Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
    Fernandez del Moral P; Litjens TT; Weil EH; Debruyne FM
    Urology; 1988 Aug; 32(2):137-40. PubMed ID: 2969641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of cancer of the prostate. Role of gonadorelin analogs].
    Steg A
    Presse Med; 1989 May; 18(20):1007-9. PubMed ID: 2524792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.